Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.55 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.55 |
| ▸ | P2RY10 | O00398 | 3/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1689951 | 0.85 | LPAR3 (0.56) | LPAR3LPAR2LPAR1P2RY10SLC6A5 | |
| SCHEMBL53526 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1P2RY10 | |
| SCHEMBL53780 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1P2RY10 | |
| SCHEMBL53844 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1P2RY10 | |
| SCHEMBL52774 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1P2RY10 | |
| SCHEMBL53469 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1P2RY10 | |
| SCHEMBL52233 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1P2RY10 | |
| SCHEMBL53710 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1P2RY10 | |
| SCHEMBL53039 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1P2RY10 | |
| SCHEMBL53145 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1P2RY10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497388-B2 | Phospholipid-analogous compounds | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN. E.V. (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20120009246-A1 | PHOSPHOLIPID-ANALOGOUS COMPOUNDS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-01-12 | — | — | US | disclosed |
| US-7939683-B2 | Phospholipid-analogous compounds | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-05-10 | — | — | US | disclosed |
| US-20100183705-A1 | PHOSPHOLIPID-ANALOGOUS COMPOUNDS | Max-Planck-Gesellschaft zur Förderung du Wissenschaften e.V. (DE) | 2010-07-22 | — | — | US | disclosed |
| US-6828453-B2 | Phospholipid-analogous compounds | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE) | 2004-12-07 | — | — | US | disclosed |
| US-20030198663-A1 | Phospholipid-analogous compounds | EIBL HANS-JORG (DE) | 2003-10-23 | — | — | US | disclosed |
| EP-1019417-B1 | PHOSPHOLIPID ANALOGUE COMPOUNDS | MAX PLANCK GESELLSCHAFT (DE) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009246-A1 | PHOSPHOLIPID-ANALOGOUS COMPOUNDS | SGMS1, DEGS1, SGMS2 | LPAR3 55/4885LPAR2 39/4885LPAR1 30/4885 |
| US-20100183705-A1 | PHOSPHOLIPID-ANALOGOUS COMPOUNDS | SGMS1, DEGS1, SGMS2 | LPAR3 30/4885LPAR2 12/4885LPAR1 11/4885 |
| US-20030198663-A1 | Phospholipid-analogous compounds | SGMS1, PHOSPHO1, DEGS1 | LPAR3 47/4885LPAR2 12/4885LPAR1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.